Affiliations
Our Editorial Team
Conor Steuer, MD
Medical ReviewerConor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Steuer received his medical degree ...
Affiliations
Expertise
Medical oncologyBoard Certifications and Training
- American Board of Internal Medicine
- Board-Certified in Hematology and Medical Oncology
Education
- Bachelor of Arts (BA) in Biology, Johns Hopkins University
- Doctor of Medicine (MD), New York University School of Medicine
Awards and Accreditation
- Castle Connolly Top Doctor
- Selected for the American Association for Cancer Research/American Society of Clinical Oncology (AACR/ASCO) Workshop on Methods in Clinical and Cancer Research, 2014
- Merit Award Recipient, American Society of Clinical Oncology (ASCO), 2015
- Member, American Society of Clinical Oncology, 2012–present
- Member, International Association for the Study of Lung Cancer (IASLC), 2014– present
- Member, American Head and Neck Society (AHNS), 2021–present
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncology. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70. Erratum in: Lancet Oncol. 2020 Jul;21(7):e341. Erratum in: Lancet Oncol. 2020 Aug;21(8):e372. Erratum in: Lancet Oncol. 2021 Oct;22(10):e428. PMID: 31838007; PMCID: PMC7461630.
Steuer, C.E., El-Deiry, M., Parks, J.R., Higgins, K.A. and Saba, N.F. (2017), An update on larynx cancer. CA: A Cancer Journal for Clinicians, 67: 31-50. https://doi.org/10.3322/caac.21386
Steuer CE, Ramalingam SS. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2018 Mar;36(7):631-632. DOI: 10.1200/jco.2017.76.8770. PMID: 29337637.
J. Remon, C.E. Steuer, S.S. Ramalingam, E. Felip, Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients, Annals of Oncology, Volume 29, Supplement 1,2018,Pages i20-i27,ISSN 0923-7534.
Bilen, M.A., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Shabto, J.M., Akce, M., Kissick, H.T., Carthon, B.C., Shaib, W.L., Alese, O.B., Pillai, R.N., Steuer, C.E., Wu, C.S., Lawson, D.H., Kudchadkar, R.R., El-Rayes, B.F., Master, V.A., Ramalingam, S.S., Owonikoko, T.K. and Harvey, R.D. (2019), The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer, 125: 127-134.
J. Remon, C.E. Steuer, S.S. Ramalingam, E. Felip, Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients, Annals of Oncology, Volume 29, Supplement 1,2018,Pages i20-i27,ISSN 0923-7534.
Bilen, M.A., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Shabto, J.M., Akce, M., Kissick, H.T., Carthon, B.C., Shaib, W.L., Alese, O.B., Pillai, R.N., Steuer, C.E., Wu, C.S., Lawson, D.H., Kudchadkar, R.R., El-Rayes, B.F., Master, V.A., Ramalingam, S.S., Owonikoko, T.K. and Harvey, R.D. (2019), The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer, 125: 127-134.